Bioelectrical Epigenetic Programming (BEP) technology is committed to its mission of providing solutions to unmet medical needs defined by regulatory medical authorities. To this end, a transparent, testable, and sustainable validation matrix that is fully compliant with medical ethics and regulatory standards has been established. Encompassing all processes from in vivo pre-clinical studies to clinical trials, this structure is executed on the basis of an advanced clinical evidence data generation architecture to safeguard data clarity.

Research Objectives and Methodology: These research initiatives were designed and conducted to comprehensively investigate and report whether the autonomous response profiles exhibited by the organism under pathological conditions can be regulated via BEP technology toward the objective of homeostasis. The findings reported by independent researchers have been categorized and modeled in accordance with Robbins & Cotran General Pathology standards; the corresponding scientific publication and regulatory approval processes have been initiated.

The matrix of results reported by independent researchers under the specified pathological categories is as follows:

*** The results of 3 distinct clinical trials pertaining to the findings listed above are currently in the phase of manuscript preparation and final editorial review for publication in international literature.

⚖️ Legal Disclaimer and Information

• Important Note: All information shared on this webpage has been prepared to summarize the scientific validation matrix, clinical evidence data generation architecture, and academic vision of Bioelectrical Epigenetic Programming (BEP) technology.

• Medical Advice and Commitment Disclaimer: The independent research findings, laboratory observations, and physiological data presented on this page do not constitute, either directly or indirectly, medical advice, diagnosis, treatment, or a clinical promise. They cannot be interpreted as a definitive commitment to recovery or a cure against any disease or pathological condition. For any diagnosis and treatment process regarding your health status, an expert physician must absolutely be consulted.

• Product Status: BEP technology and the systems developed on the basis of this technology are not pharmacological drugs but fall under the classification of medical devices. The operating principles of the technology are built upon host-directed biophysical mechanisms and homeostasis regulation.

• Regulatory and Certification Status: Scientific publication preparations as well as official registration, certification, and regulatory processes before national and international medical authorities (TİTCK, EU MDR, FDA, etc.) mentioned in the text are actively pursued. The academic and pre-clinical/clinical data presented on this page cannot be evaluated as a commercial sale of the device, a marketing claim outside the approved indication boundaries, or an element of advertising.

• Target Audience and Intended Use: In accordance with the principles of medical ethics, transparency, and scientific testability, this content is structured primarily to inform healthcare professionals, academicians, researchers, and solution partners. The Robbins & Cotran General Pathology standards referenced on the page are utilized solely to model the technology's mechanisms of action within the scientific literature and do not intend to create a perception of unfair commercial competition.